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A B S T R A C T
Hookworms are intestinal nematode parasites that infect nearly half a billion people and are globally one of the
most important contributors to iron-deﬁciency anemia. These parasites have signiﬁcant impacts in developing
children, pregnant women and working adults. Of all the soil-transmitted helminths or nematodes (STNs),
hookworms are by far the most important, with disease burdens conservatively estimated at four million DALYs
(Disability-Adjusted Life Years) and with productivity losses of up to US$139 billion annually. To date, mainly
one drug, albendazole is used for hookworm therapy in mass drug administration, which has on average∼80%
cure rate that is lower (< 40%) in some places. Given the massive numbers of people needing treatment, the
threat of parasite resistance, and the inadequacy of current treatments, new and better cures against hookworms
are urgently needed. Cry5B, a pore-forming protein produced by the soil bacterium Bacillus thuringiensis (Bt) has
demonstrated good eﬃcacy against Ancylostoma ceylanicum hookworm infections in hamsters. Here we broaden
studies of Cry5B to include tests against infections of Ancylostoma caninum hookworms in dogs and against
infections of the dominant human hookworm, Necator americanus, in hamsters. We show that Cry5B is highly
eﬀective against all hookworm parasites tested in all models. Neutralization of stomach acid improves Cry5B
eﬃcacy, which will aid in practical application of Cry5B signiﬁcantly. Importantly, we also demonstrate that the
anti-nematode therapeutic eﬃcacy of Cry5B is independent of the host immune system and is not itself negated
by repeated dosing. This study indicates that Bt Cry5B is a pan-hookworm anthelmintic with excellent properties
for use in humans and other animals.
1. Introduction
Hookworms (Necator americanus, Ancylostoma duodenale,
Ancylostoma ceylanicum) are the most important of the soil-transmitted
helminths or soil-transmitted nematodes (STNs) of humans, which also
include large roundworms (Ascaris lumbricoides) and whipworms
(Trichuris trichiura). These parasitic intestinal nematodes are one of the
most prevalent parasites globally, infecting∼ half a billion people
(Pullan et al., 2014). Infection by hookworm is associated with sig-
niﬁcant growth stunting in children, cognitive defects, anemia, mal-
nutrition, lethargy (“germ of laziness”), reduced school attendance and
educational status in children, and loss of worker productivity (Bethony
et al., 2006; Bartsch et al., 2016; Loukas et al., 2016). Retrospective
analyses of hookworm infections in the southern United States circa
early 1900's demonstrated that children who grew up with hookworms
had future income reduced ∼40% compared to their peers and that
hookworms were responsible for ∼22% of the economic gap and
∼50% of the literacy gap between Northern and Southern States
(Bleakley, 2007). Their impact on human health in the world today is
tremendous and likely underestimated; hookworms are one of the most
important parasites of our time (Bartsch et al., 2016; Loukas et al.,
2016).
Current global strategy against hookworms involves mass drug ad-
ministration (MDA) with single dose benzimidazoles, either albenda-
zole or mebendazole (World Health Organization, 2013). Of these two,
albendazole is clearly superior as a single dose therapy, with an average
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reported cure rate about 80% vs 33% for mebendazole and an average
reported egg reduction rate of about 90% vs 61% for mebendazole
(Moser et al., 2017). However, there are increasing reports of instances
where the average cure rate is not achieved. For example, there are
reports of albendazole treatment failure in Ghana, low cure rates in Lao
PDR and Nigeria (respectively, 36% and 15%), and apparent loss of
eﬃcacy in a population with low hookworm burdens in Sri Lanka after
years of deworming (Gunawardena et al., 2008; Soukhathammavong
et al., 2012; Edelduok et al., 2013; Humphries et al., 2017). Further-
more, known benzimidazole resistance alleles exist in natural hook-
worm populations (e.g., in Kenya) and hookworms, with their rapid life
cycle and high turnover in the environment, are extremely well suited
towards the development of resistance towards benzimidazoles
(Diawara et al., 2013). Indeed, resistance to benzimidazoles is wide-
spread in veterinary medicine and has been demonstrated for numerous
nematode parasites (Kaplan, 2004; Wolstenholme et al., 2004; Von
Samson-Himmelstjerna et al., 2007). Although documented anthel-
mintic resistance to benzimidazoles has not yet been reported in human
MDA, the lower-than-expected eﬃcacy in places and the experience
from veterinary medicine indicate that the need for new anthelmintics
can be anticipated and is urgent.
Despite the importance of hookworms and the general recognition
that current treatments are insuﬃcient to eliminate parasites, few al-
ternative therapies are being developed. One recently developed an-
thelmintic, tribendimidine, has similar average eﬃcacy against hook-
worms as albendazole (Steinmann et al., 2008). Tribendimidine is a
nicotinic acetylcholine receptor (nAChR) agonist (Hu et al., 2009), a
class of molecules for which parasite resistance in veterinary medicine
and human medicine can develop (Roepstorﬀ et al., 1987; Bjørn et al.,
1990; Reynoldson et al., 1997; Sacko et al., 1999; Kopp et al., 2007).
Thus, development of additional treatment options in the pipeline are
urgently needed. One such promising option is Cry5B, a Bacillus thur-
ingiensis (Bt) three-domain crystal (Cry) protein that has been shown to
be eﬀective against A. ceylanicum hookworm infection in hamsters
(Cappello et al., 2006; Hu et al., 2012; Hu et al., 2013b). Cry5B is also
eﬃcacious against Ascaris infections in pigs and against important ve-
terinary targets in vitro (Kotze et al., 2005; Urban et al., 2013). Three-
domain Bt Cry proteins are generally considered non-toxic and safe to
vertebrates and are used globally to control insects that damage crops
and carry disease (Betz et al., 2000; Koch et al., 2015). They are EPA/
FDA approved for human ingestion and are a signiﬁcant part of our
food chain, e.g., > 80% of all corn grown in the U.S. expresses a Bt Cry
protein (Dively et al., 2016). Furthermore, mechanistic studies of Cry5B
itself indicate that the obligate receptor for Cry5B in nematodes is an
invertebrate-speciﬁc glycolipid (Griﬃtts et al. 2003, 2005). Thus,
Cry5B is mechanistically safe to vertebrates, which lack the biosyn-
thetic pathway to make such receptors. Forward genetic screens for
Cry5B resistance in Caenorhabditis elegans suggest that resistance to
Cry5B is less likely to develop in nematodes against Cry5B than against
benzimidazoles and nAChR agonists (Hu et al., 2010b).
To be eﬀective as a human therapeutic against this globally im-
portant parasite, it is important to establish if Cry5B is broadly active
against hookworms. We therefore set out to address Cry5B eﬃcacy
against N. americanus, the dominant hookworm parasite in humans and
the most diﬃcult of the hookworms to treat, as, for example, it is more
resistant to ivermectin than Ancylostoma (Behnke et al., 1993; Lawn
et al., 2003; Hotez, 2011). Furthermore, we set out to test Cry5B against
hookworms in non-rodent models of the human gastrointestinal tract,
most notably Ancylostoma caninum infections in dogs, which are con-
sidered one of the best models for human hookworm studies. We also
set out to address other key issues critical for Cry5B progression as a
novel bacterial protein-based human therapy for hookworms by de-
termining: 1) if the anthelmintic activity of Cry5B requires the immune
system to expel parasites; 2) if a host response to Cry5B builds up after
repeated doses that inhibits the ability of the protein to subsequently
function; and 3) whether neutralization of stomach acid improves
protein eﬃcacy in order to allow for lower costs and signiﬁcant re-
ductions in dosing.
2. Materials and methods
2.1. Medium and reagents
Reagents for hookworm culture medium (HCM): RPMI 1640, Fetal
Bovine Serum (FBS), Penicillin-Streptomycin and Fungizone
Antimycotic were all purchased from Gibco, U.S.A. Dexamethasone 21-
phosphate disodium salt (DEX) (Cat# D1159-5G) and cimetidine (Cat#
C4522-5G) were purchased from Sigma-Aldrich, USA. Cry5B, Bt Cry5B
spore-crystal lysate (SCL), and Bt spore lysate (SL; spores plus lysate
with no Cry5B) were prepared as described before (Marroquin et al.,
2000; Griﬃtts et al., 2001). SL alone has no impact on intestinal ne-
matode burdens ((Hu et al., 2010a, b); Fig. 5). DEX was used to immune
suppress the hamsters for N. americanus-related experiments. The con-
centration of DEX in the drinking water and subcutaneously injected
was 1mg/L and 4mg/mL, respectively. Cimetidine was prepared and
dosed as described (Stepek et al., 2007). All drugs used in the in vivo
canine study (maropitant, acepromazine, propofol, dexmedetomidine,
atipamezole, famotidine) were purchased from the Cornell University
Hospital for Animals pharmacy.
2.2. Animals and parasites
A. ceylanicum was maintained as previously reported (Hu et al.,
2012). To maintain the N. americanus life cycle, hamsters were im-
munosuppressed with DEX, as has been previously described (Tritten
et al., 2011). Three to four-week-old male Golden Syrian hamsters
(HsdHan:AURA) were purchased from Envigo (U.S.A) and were in-
fected at approximately 4–5 weeks of age with either ∼150 A. ceyla-
nicum third-stage infectious larvae (L3i) orally or∼400 N. americanus
L3i larvae subcutaneously. Hamsters were provided with food and
water (ad libitum). Ancylostoma caninum L3i were grown in charcoal
culture as previously described (Lee et al., 2014). The Heligmosomoides
polygyrus bakeri life cycle was maintained at the United States Depart-
ment of Agriculture (USDA) as described (Camberis et al., 2003). Two
purpose-bred female beagles, 6 months of age, were inoculated per os
with 1000 A. caninum L3i larvae. Five-month old male and female
STAT6 KO mice born and maintained on-site from breeding pairs pur-
chased from Jackson Laboratories were inoculated with 200 H. poly-
gyrus bakeri L3i larvae per os.
All animal experiments were carried out under protocols approved
by the University of Massachusetts Medical School (hamsters), Baylor
College of Medicine (hamsters), Cornell University (dogs), and USDA
(mice) Animal Care and Use Committees (IACUC). All housing and care
of laboratory animals used in this study conform to the NIH Guide for
the Care and Use of Laboratory Animals in Research (see 18-F22) and
all requirements and all regulations issued by the USDA, including
regulations implementing the Animal Welfare Act (P.L. 89-544) as
amended (see 18-F23).
2.3. In vitro assays
Adult N. americanus in vitro assays were carried out as described for
A. ceylanicum (Hu et al. 2012, 2013a), with the exception that there
were only three worms per well and that the hookworms were not se-
parated by gender.
2.4. In vivo studies
2.4.1. A. caninum
Two purpose-bred female beagles, 6 months of age, were inoculated
per os with 1000 A. caninum L3i (day 0). Only two beagles were used
due to budgetary constraints for this pilot dog study. Patency of
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infection was conﬁrmed on day 21 post-inoculation (p. i.) by fecal
centrifugal ﬂotation using a sugar solution with a speciﬁc gravity of 1.3.
Pre-treatment hookworm burdens were determined using capsule en-
doscopy (Endocapsule EC-10 System, Olympus America) (Lee et al.,
2014) on day 41 p. i. To enable deployment of the endoscopic capsule
directly into the small intestine, dogs were brieﬂy anesthetized. Dogs
were fasted overnight, and pre-medicated with 1mg/kg of maropitant
SQ and 0.04mg/kg acepromazine IM. A 4mg/kg propofol bolus was
administered IV to allow for intubation with a cuﬀed endotracheal tube.
Thereafter, propofol was infused at a rate of 0.4–0.6mg/kg IV as
needed. A modiﬁed ﬂexible gastroscope was used to deliver the endo-
scopic capsule into the proximal duodenum. Dogs were outﬁtted with a
custom jacket holding the antenna pad and image recorder, and then
recovered from anesthesia. An Elizabethan collar equivalent was placed
around the dogs’ necks to prevent bite damage to the instruments. Dogs
were regularly monitored during intestinal imaging, and recordings
were stopped once the capsule was conﬁrmed to be in the colon based
on real-time images. Data were downloaded onto a laptop and reviewed
by a single endoscopist.
Fecal egg counts were performed on day 41 p. i. using the Stoll
method (Marsden, 1984) with the following modiﬁcations: 1) 4.00 g of
feces were weighed out and added to the Stoll ﬂask, which was then
ﬁlled to the 60mL mark with 0.1 N NaOH; 2) two aliquots were counted
to arrive at an average egg count for each sample; and 3) corrections
were made for fecal consistency by weighing a sample of the feces
before and after overnight incubation at 105 °C, thus resulting in a ﬁnal
egg count based on dry fecal weight. On day 42 p. i. dogs were given
1.5 mg/kg famotidine PO and sedated with 375 μg/m< sup>2< /
sup>dexmedetomidine IM 30min prior to gavage delivery of a
40mg/kg Cry5B suspension. Sedation was reversed with 3750 μg/
m< sup>2</sup> atipamezole IM. The dogs were fed their normal
daily meal 2 h after the Cry5B treatment. Capsule endoscopy and fecal
egg counts were repeated on day 43 p. i. to assess the eﬀect of the ﬁrst
treatment. A second dose of 40mg/kg Cry5B was administered on day
44 p. i. in the manner described above. A ﬁnal capsule endoscopy and
fecal egg count were performed post-treatment on day 49 p. i.
2.4.2. N. americanus
Infected hamsters (n=10) were housed individually from day 20 p.
i. onwards. On days 55 and 56 p. i. a fecal sample was collected from
each hamster and processed as described (Hu et al. 2012, 2013b). On
the basis of the fecal egg counts (FECs), N. americanus-infected hamsters
were either assigned to the control or Cry5B treatment groups (roughly
equal egg counts/group) and were treated per os with either water or
Cry5B SCL, respectively, on day 56 p. i. Four days later, the hamsters
were euthanized, and worm burdens were determined (Hu et al. 2012,
2013b).
2.4.3. A. ceylanicum
The A. ceylanicum in vivo experiments were carried out as described
(Hu et al. 2012, 2013a,b). Cimetidine was gavaged 15min ahead of
Cry5B administration.
2.4.4. H. polygyrus bakeri
Five-month old male and female STAT6 KO mice were inoculated
per os with 200 H. polygyrus bakeri L3i. The infected mice were treated
on days 7 and 9 p. i. per os with SL or Cry5B SCL and necropsied three
days after the last treatment at day 12 p. i.
2.5. Statistical analyses
Prism v. 7 was used for all analyses and graphs. For all comparisons
including just two groups, a one-tailed Mann-Whitney test was used.
For all comparisons involving two groups relative to a control group,
one-way analysis of variance (ANOVA) with Dunnett's post-test was
used.
3. Results
3.1. Cry5B is broadly active against hookworms, including in dogs
We tested the ability of Cry5B SCL to target A. caninum hookworm
infections in dogs (Fig. 1). Cry5B SCL was gavaged into A. caninum-
infected dogs (two doses spaced two days apart). One day after the ﬁrst
treatment, signiﬁcant drops in hookworm burdens were seen (56% re-
duction based on arithmetic means; Table 1). Five days after the second
treatment, Cry5B eﬀected a near-complete elimination of hookworm
infection in the dogs, with an overall 95% reduction in hookworm
burdens and 91% reduction in fecal egg counts (Fig. 1 and Table 1).
To determine if Cry5B might also be active against N. americanus,
we initially tested the ability of Cry5B to intoxicate adult N. americanus
hookworms in vitro. Relative to buﬀer-only controls, strong intoxication
of N. americanus hookworms was seen with Cry5B as reﬂected by a
signiﬁcant reduction in motility index (Fig. 2A). The kinetics of N.
americanus intoxication with Cry5B were similar to that of A. ceylanicum
(Cappello et al., 2006).
Based on positive in vitro results, we next tested the ability of Cry5B
SCL to impact N. americanus infections in vivo. We found that a single
Fig. 1. Eﬃcacy of Cry5B SCL against A. caninum infections in dogs. Two dogs were pre-treated with famotidine and dexmedetomidine, treated with Cry5B, and post-
treated with atipamezole. The dose of Cry5B was 40mg/kg on day 42 and day 44 p. i. Shown are (A) average hookworm burdens based on capsule endoscopy and (B)
average fecal egg counts (eggs per gram of feces or EPG) ﬁve days after the second treatment.
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dose of Cry5B SCL delivered per os at 40mg/kg (Cry5B content) sig-
niﬁcantly reduced hookworm burdens by 88.3% and FECs by 94.8%
(Fig. 2B and C; Supplementary Table 1), with three of the ﬁve hamsters
completely cured. Thus, Cry5B is active against the dominant human
hookworm species. For comparison, we tested Cry5B SCL at the same
dose (40mg/kg per os) in A. ceylanicum-infected hamsters. As shown in
Fig. 2D and E, this dose of Cry5B resulted in a complete cure of A.
ceylanicum hookworms in hamsters (100% elimination of parasites).
The dosing used in the above studies is low on a molar level– e.g.,
40 mg/kg Cry5B is ∼300 nmol/kg, which is equivalent to 80 μg/kg
albendazole (a dose of albendazole that has no eﬀect on hookworm
burdens in hamsters; unpublished observations). Thus, Cry5B is far
more potent than albendazole on a molecule by molecule basis.
However, we recognize that 40mg/kg Cry5B is a signiﬁcant dose by
mass. Since>99.9% of Cry5B is rapidly degraded in stomach acid (Hu
et al., 2010a), we hypothesized that protection from stomach acid
should improve eﬃcacy. Previous attempts to protect Cry5B from sto-
mach acid using nanoparticles failed, likely due to slow release kinetics
(Wu et al., 2015). To circumvent the challenges with formulation
strategies, we tested whether direct inhibition of stomach acid proteo-
lysis would improve Cry5B eﬃcacy. We pre-treated A. ceylanicum
hookworm-infected hamsters with cimetidine, a histamine H2 receptor
antagonist that inhibits stomach acid production (and thus pepsin ac-
tivity) and pepsin secretion (Burland et al., 1975; Schlippert, 1978).
Fifteen minutes following cimetidine treatment, the hamsters were
given Cry5B SCL at two diﬀerent doses. Control groups included no pre-
treatment with cimetidine or cimetidine alone. Whereas cimetidine
alone had no impact on hookworm burdens, pre-gavage with cimeti-
dine improved Cry5B SCL eﬃcacy (Fig. 3A and B; Supplementary
Table 1), which was reproducible (data not shown). Similar results were
found using puriﬁed Cry5B protein (Fig. 3C and D, Supplementary
Table 1).
3.2. Cry5B anthelmintic activity does not require the Th2 immune response
Since Cry proteins have never been used therapeutically in mam-
mals before, it was unclear how the host immune system modulates
Cry5B activity. Because Cry5B is able to largely clear N. americanus
infections in hamsters immunosuppressed with DEX, these data suggest
that Cry5B does not require an intact host immune system to act as an
anthelmintic. To independently conﬁrm this result, we tested the ability
of Cry5B to act on the parasitic nematode H. polygyrus bakeri in mice for
which the STAT6 gene has been knocked out. STAT6−/− mice lack a
strong Th2 response, which plays a central role in host-mediated in-
testinal nematode expulsion (Maizels and Holland, 1998; Finkelman
et al., 2004; Bao and Reinhardt, 2015). We found that Cry5B treatment
in STAT6−/− mice (2×40mg/kg) infected with H. polygyrus bakeri
resulted in a signiﬁcant reduction in worm burdens (53% reduction)
and fecal egg counts (78% reduction; Fig. 4A and B; Supplementary
Table 1), consistent with previously published eﬀects of Cry5B on H.
polygyrus bakeri infections in immunocompetent mice (Hu et al.,
2010a). Taken together, our data demonstrate that Cry5B has a direct
eﬀect on the parasite and does not require an intact immune system to
function as an anthelmintic.
3.3. Repeated dosing does not abrogate Cry5B eﬃcacy
Conversely, it is important to establish whether there is a host re-
sponse that might weaken Cry5B activity over time. As Cry proteins
have never been used therapeutically, it was unclear whether repeated
Cry5B dosing might result in a host response that would neutralize its
anthelmintic eﬀects. We set up a repeated dosing experiment to address
this question (Fig. 5A). We pre-treated uninfected hamsters with two
Cry5B SCL doses spaced two weeks apart. Two weeks after the second
“pre-dose,” hamsters were infected with A. ceylanicum hookworms.
Eighteen days after infection, these same hamsters were then given a
third “treatment dose” of Cry5B SCL to test its eﬃcacy in hamsters with
prior Cry5B SCL dosing. The placebo control for this group of hamsters
was a second set of hamsters treated before and after infection with the
same timing except we administered SL lacking Cry5B instead of SCL
with Cry5B. The eﬃcacy of these treatment groups was then compared
to three other sets of hamsters that were not given pre-doses but were
infected at the same time as the previous two groups. These latter three
sets of hamsters were then given a treatment dose of Cry5B SCL, SL (no
Cry5B), or water at the same time as the pre-dosed groups.
The results are shown in Fig. 5B and Supplementary Table 1.
Treatment with SL, whether given as part of a pre-treatment regimen or
not, had no impact on hookworm burdens relative to water control.
Conversely, treatment with Cry5B was equally eﬃcacious whether
given after a “pre-dose” regimen or not. Thus, repeated dosing with
Cry5B had no impact on its ability to eﬀect a cure on a subsequent dose.
In addition, there was no apparent toxicity (e.g., no diarrhea, in-
appetence, agitation) associated with these repeated treatments. These
results were reproducible using puriﬁed Cry5B protein (Fig. 5C;
Supplementary Table 1).
4. Discussion
Here we demonstrate that the promising new anthelmintic, Cry5B,
is eﬀective against both genera of human hookworms. Hookworms are
the single-most important intestinal nematode parasite in terms of
morbidity, DALYs, and priority for treatment. Hookworms, unlike
whipworms and large roundworms, are comprised of multiple species
within two diﬀerent genera, each of which can have diﬀerent sus-
ceptibilities to anthelmintics. Notably, Necator is generally much less
susceptible to ivermectin than Ancylostoma and hence ivermectin is not
an approved drug for MDA to control intestinal nematodes (Naquira
et al., 1989; Behnke et al., 1993; Richards et al., 1995; Lawn et al.,
2003). In these experiments, we also found that Cry5B eﬃcacy was
aided by protection from stomach degradation by pepsin using the
proton pump inhibitor cimetidine.
Cry5B is also highly active against A. caninum hookworm infections
in dogs. The dog GI tract is an excellent model for the human GI tract,
and hookworm infection in dogs is one of the best models for hook-
worm infection in humans (Hotez et al., 1996; Fujiwara et al., 2006).
We similarly found in a prior study that Cry5B was eﬃcacious against
Ascaris in pigs (Urban et al., 2013). Taken together and given that Cry
proteins are generally safe and that the Cry5B receptor is an in-
vertebrate-speciﬁc molecule, our data predict that Cry5B will safely
cure hookworms and Ascaris in humans. Our pilot dog study highlights
the need for the development of an enteric-protected formulation and
further dose-response and dose-timing studies in this system. We don't
know, for example, what would have happened at lower doses or if only
a single dose had been used. For example, a 56% drop in hookworm
burdens was seen one day after the ﬁrst dose, before a second dose was
Table 1
Worm burdens and EPGs in Fig. 1.
Worm burden EPG
Before
treatment
One day
after
ﬁrst
dose
Five days
after
second
dose
Before
treatment
Five days
after
second
dose
Dog #1 84 43 4 15750 1590
Dog #2 56 19 3 9412 573
Arithmetic
mean (%
reduction)
70.0 31.0
(56%)
3.5 (95%) 12581.0 1081.5
(91%)
Geometric mean
(%
reduction)
68.6 28.7
(58%)
3.5 (95%) 12175.4 954.6
(92%)
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then given the following day with 95% clearance of hookworms in this
preliminary study (multiple doses of anthelmintics over the course of a
few days are not uncommon for treatment of intestinal helminths in
dogs (Roberson and Burke, 1982)). An additional challenge in dogs is
that, in general, they have slower gastric emptying in the fed state and
faster small intestinal transit than humans (Dressman, 1986), which
respectively would lead to more degradation of Cry5B in the stomach
and a relatively short contact time between Cry5B and hookworms
residing in the small intestine. Based on our results here, expanded
dosing studies in dogs and improved enteric formulations are re-
commended for future studies.
We also addressed two important questions related to Cry5B activity
and the host. First, we demonstrated that Cry5B eﬃcacy does not
require an intact immune system or a functional Th2 response in the
host. Cry5B is eﬃcacious against N. americanus in hamsters treated with
dexamethasone, even though corticosteroid therapy inhibits the ham-
ster immune system from expelling intestinal parasites naturally.
Furthermore, Cry5B is active in STAT6−/− mice that lack the Th2
response, which plays a major role in parasite expulsion. Taken to-
gether, these data indicate that Cry5B anthelmintic activity is due to
direct action against the parasites in vivo.
Second, we demonstrated that repeated dosing of Cry5B over time
does not lead to its loss of activity or to host toxicity. Our experimental
design for this test used three oral doses in less than six weeks, which is
more frequent than MDA for STNs, which typically involves dosing 1-2
times per year. Despite the fact that Cry proteins are used in massive
Fig. 2. Eﬃcacy of Cry5B against N. americanus and A. ceylanicum. (A) Intoxication of N. americanus adults in vitro over time at a dose of 250 μg/mL Cry5B puriﬁed
protein (n=6/dose/repeat, average of 2 repeats). (B) N. americanus hookworm burdens in placebo (water control) versus Cry5B treatment. Here and in similar
ﬁgures, each dot represents hookworm burden in an individual hamster; long horizontal bar represents the average and short horizontal bars represent standard
error. (C) N. americanus fecal egg counts (EPG) before treatment and after treatment with placebo (water control) or Cry5B. Here and in similar ﬁgures, each bar
represents the average of all hamsters; error bar represents standard error. (D) A. ceylanicum hookworm burdens in placebo (water control) versus Cry5B treatment.
(E) A. ceylanicum fecal egg counts (EPG) before treatment and after treatment with placebo (water control) or Cry5B. The dose in vivo for B-E is 40mg/kg Cry5B,
delivered as SCL.
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quantities around the world in agriculture and vector control, and are a
prominent part of our food chain, Cry proteins have not been used as an
ingested therapeutic, e.g., to control intestinal nematodes in mammals.
We note that although the vast majority of safety studies show no
concerns with Bt Cry proteins and Bt Cry proteins have an excellent
safety record in our food supply, a few previous studies showing im-
munogenetic eﬀects in rodents have been reported (Hammond et al.,
2013). We did not directly test for similar immunogenetic eﬀects here,
Fig. 3. Inhibition of pepsin via cimetidine improves Cry5B eﬃcacy. (A) A. ceylanicum hookworm burdens in hamsters treated with spore lysate (SL), cimetidine alone
(Cim only), or Cry5B SCL at the indicated dose without or with (+Cim) a dose of cimetidine that inhibits pepsin activity 15 min prior to SCL treatment. (B)
Corresponding fecal egg counts (EPG) for experiment in A before treatment and after treatment. (C, D) Same experiment as in (A, B) except using puriﬁed Cry5B.
Fig. 4. Cry5B is eﬃcacious in the absence of
a Th2 immune response. (A) H. polygyrus
bakeri worm burdens in placebo (SL control)
versus Cry5B SCL treatment in STAT6−/−
mice. (B) H. polygyrus bakeri fecal egg counts
in placebo (SL control) versus Cry5B SCL
treatment in STAT6−/− mice. The Cry5B
dose is 2× 40mg/kg. For comparison, a
single 100mg/kg dose reduced H. polygyrus
bakeri burdens 67% in immunocompetent
mice (Hu et al., 2010a).
Y. Hu et al. IJP: Drugs and Drug Resistance 8 (2018) 287–294
292
although the data in Fig. 5 indicate that a localized immune response to
neutralize the protein in the intestine is not apparent. In addition, there
is some question as to the relevance of these previous studies showing
immunogenetic eﬀects (e.g., intranasal route of administration, lack of
reproducibility, lack of proper controls, presence of mycotoxins, and
high dosing), and there are numerous other studies that contradict
these immunogenic ﬁndings (Hammond et al., 2013; Reiner et al.,
2014; Tan et al., 2016; Sánchez and Parrott, 2017).
In summary, our data here indicate that Cry5B, a novel mechanism-
of-action oral, protein anthelmintic, broadly cures hookworms upon
repeated dosing in a wide range of hosts, with or without a robust
immune system, and will likely be eﬀective in humans.
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